Drug Profile

LIN 2102

Alternative Names: LIN-2102; SLN-12140

Latest Information Update: 11 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Linno Pharmaceuticals
Class Eye disorder therapies; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins; Single-domain antibodies; Urologics
Mechanism of Action Complement system protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

04 Feb 2026 Linno Pharmaceuticals plans a phase II trial for Paroxysmal nocturnal haemoglobinuria in China (SC) in February 2026 (NCT07387302)
02 Jul 2025 Phase-I clinical trials in Dry age-related macular degeneration in China (Parenteral) prior to July 2025 (Linno Pharmaceuticals pipeline, July 2025)
02 Jul 2025 Phase-I/II clinical trials in Acute kidney injury in China (Parenteral), prior to July 2025 (Linno Pharmaceuticals pipeline, July 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com